Role of persistent amenorrhea in bone mineral metabolism of young hemodialyzed women  by Weisinger, José R. et al.
Kidney International, Vol. 58 (2000), pp. 331–335
Role of persistent amenorrhea in bone mineral metabolism of
young hemodialyzed women
JOSE´ R. WEISINGER, LEYDA GONZALEZ, HECTOR ALVAREZ, EDDY HERNANDEZ,
RAU´L G. CARLINI, FREYA CAPRILES, MERCEDES CERVIN˜O, RUBY MARTINIS,
VIRGILIO PAZ-MARTI´NEZ, and EZEQUIEL BELLORI´N-FONT
Division of Nephrology, Hospital Universitario de Caracas, Universidad Central de Venezuela and Fresenius Medical Care of
Venezuela, Caracas, Venezuela
with normal menstruating women on dialysis. The possibleRole of persistent amenorrhea in bone mineral metabolism of
impact of these results in the natural history of the uremicyoung hemodialyzed women.
osteodystrophy remains to be determined.Background. Chronic renal failure in women is frequently
associated with endocrine disturbances leading to menstrual
disorders. However, most studies on renal osteodystrophy have
not taken into account the possible role of these hormonal
The term renal osteodystrophy has been widely ac-disturbances on the pathogenesis of bone alterations seen in
cepted to define the bone lesions associated with chronicthese patients. In the present study, we evaluated bone mineral
metabolism in a group of young hemodialyzed women with renal failure. It includes diseases that affect the control
persistent amenorrhea and compared them with similar women of bone remodeling, such as high turnover bone disease
with regular menstruation. caused basically by secondary hyperparathyroidism orMethods. We studied 74 women who were further subdi-
low turnover in the form of adynamic bone disease andvided into 43 women with regular menstrual periods and 31
women with persistent amenorrhea, defined as the absence of osteomalacia, usually associated to vitamin D deficiency
menstrual bleeding for more than six months. In all patients, or aluminum toxicity [1]. However, little concern has
we performed a bone mineral density (BMD) analysis and been given to the possible role of estrogen deficiency in
simultaneously evaluated different biochemical parameters, in-
the pathogenesis of uremic bone disease. Indeed, sincetact parathyroid hormone (iPTH), sexual hormone determina-
renal osteodystrophy develops at a faster rate and repre-tions that included total estradiol, follicle-stimulating (FSH),
and luteinizing hormone and markers of bone resorption such sents a major clinical problem, it has dominated the
as the procollagen type 1 cross-linked carboxy-terminal telo- contribution that postmenopausal osteoporosis could
peptide (ICTP). have in the bone alterations observed in the female ure-Results. Serum calcium, phosphorus, and iPTH were similar
mic patient. This is particularly important since uremicin both groups. Serum alkaline phosphatase was higher in
women frequently have early menopause or anovulatoryamenorrheic women. Although the total serum estradiol con-
centration was normal in the amenorrheic women when com- cycles with hypoestrogenism, an important hormonal al-
pared with nonuremic women, the values were significantly teration frequently associated with osteoporosis [2].
lower than those in regularly menstruating women. Serum FSH
As shown by several authors, the number of patientsand ICTP values were significantly higher in the amenorrheic
with adynamic bone disease as a form of uremic osteo-women. Trabecular BMD in the lumbar spine was also signifi-
cantly lower in the amenorrheic women compared with regu- dystrophy has increased during the recent years [3]. At
larly menstruating dialysis patients. Lumbar spine BMD and the same time, similarities between postmenopausal os-
total estradiol levels correlated significantly in the amenorrheic teoporosis and adynamic bone disease of uremia havegroup.
been suggested [4]. Increased plasma levels of bone re-Conclusions. These studies show that persistent amenor-
sorpting cytokines [interleukin-1 (IL-1), IL-6, IL-11, andrheic young women on dialysis have lower trabecular BMD
and evidence of increased bone resorption when compared tumor necrosis factor-a (TNF-a)] as well as naturally
occurring inhibitors of IL-1 and TNF-a have been found
in estrogen deficiency and uremic patients undergoingKey words: bone mineral density, osteoporosis, menopause, anovolua-
tory cycles, estrogen replacement. hemodialysis or continuous ambulatory peritoneal dial-
ysis [5–12]. In addition, sex steroids act directly on the
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Table 1. Age, time on dialysis, and duration of renal disease inrisk for renal bone disease and postmenopausal osteopo-
normal menstruating and persistent amenorrheic women
rosis. To further evaluate the possible relationship be-
Menstruating Persistenttween estrogen levels and changes in bone mass in hemo-
women amenorrheadialyzed women, we compared a group women with
Number of patients 43 31persistent early amenorrhea with aged-matched men-
Age years 35.469.2 38.268.9
struating women under similar conditions of dialysis Time on dialysis months 59.1646.3 53.8639.1





One hundred twenty-seven women were evaluated
Table 2. Serum biochemical parameters in menstruating andfrom a total of 276 patients under treatment in the dial-
persistent amenorrheic womenysis units of the University Hospital of Caracas and Fre-
senius Medical Care of Venezuela. Of these, 74 (58.3%) Menstruating Persistent
Serum values women amenorrheawere younger than 50 years and were subdivided in two
Creatinine mg/dL 13.763.2 10.364.1groups: one with regular menstrual periods (N 5 43)
Calcium mg/dL 9.1660.78 9.3561.23and the other with persistent amenorrhea, defined as the
Phosphorus mg/dL 5.861.9 5.361.8
absence of menstrual bleeding exceeding a period of Alkaline phosphatase IU/L 136.56128 321.26112a
Estradiol pg/mL 315.4641.8 98.25624.1btime of six months (N 5 31). None of the patients had
FSH mL U/mL 12.7627.3 29.7632.4cprevious evidence of diseases, other than chronic renal
Luteinizing Hormone mL U/mL 21.03641.9 30.1633.8
failure, that could affect bone metabolism. Patients who iPTH pg/dL 582.86387 5216465
ICTP lg/L 50.1569.4 72.52614.8drecently had been treated with estrogen, progesterone,
corticosteroids, anticonvulsants, fluoride, bisphospho- Abbreviations are: FSH, follicle stimulating hormone; iPTH, intact parathy-
roid hormone; ICTP, procollagen type-1 cross-linked carboxy terminal telopep-nates, or calcitonin were excluded from the study. An
tide.
informed consent was obtained from all subjects. aP , 0.01; bP , 0.001; cP , 0.01; dP , 0.05
Biochemical assays
Serum levels of total calcium, phosphorus, alkaline
Statistical analysisphosphatase, blood urea nitrogen, and creatinine were
analyzed by standard photometric methods. Hormone Results are presented as mean 6 SD. Comparisons
between two groups of data were performed by Student’slevels of total estradiol, follicle-stimulating hormone
(FSH), and luteinizing hormone (LH) were assayed by t-test for unpaired observations (two-tailed). Compari-
chemiluminescence with an Elecsys 1010 (Boehringer sons between two variables were performed by linear
Mannheim GmbH Diagnostic, Mannheim, Germany). regression analysis. A P value of , 0.05 was considered
Intact PTH was determined by an immunoradiometric significant.
assay (Nichols Institute Diagnostics, San Juan Capis-
trano, CA, USA). A serum marker of bone resorption,
RESULTSprocollagen type 1 cross-linked carboxy-terminal telo-
From 127 women on dialysis, 53 were postmenopausalpeptide (ICTP), was analyzed by radioimmunoassay
and older than 50 years of age (61.7 6 7.9 years). The(Orion Diagnostica, Espoo, Finland).
duration of amenorrhea of these women was 174 6 103.9
Bone density measurements months, and only six of them were on regular hormone
replacement therapy (11.3%). All of them were excludedBone mineral density (BMD) of lumbar spine and
from the study. The remaining 74 women with a meanfemur were performed by dual x-ray absorptiometry
age of 36.5 6 9.1 years were included in the study. Pa-(DEXA), with a DPX-L densitometer (Lunar Corpora-
tients were separated into two groups: one with regulartion, Madison, WI, USA). The results were expressed
menstrual periods (N 5 43) and the other with persistentin grams and were divided by the projected area of the
amenorrhea (N 5 31).bone to derive the BMD in grams per square centimeter.
Mean age, duration of renal disease, time on dialysis,To evaluate patients of different ages, we used the Z
and management of renal osteodystrophy were similarscore, which compares the value of every patient with
in the normal menstruating and amenorrheic womenan age- and gender-matched control population. The
(Table 1). The time of untreated amenorrhea in theprecision error of the BMD analysis in our laboratory
amenorrheic group was 48.4 6 38.9 months.was 0.7% for the whole body, 1% for anteroposterior
spine, and 1.7% for the femoral neck. Blood biochemical parameters are shown in Table 2.
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Table 3. Bone mineral density in lumbar spine (L2-L4) and femoral





Z score (SD) 0.1260.81 21.1461.2b
Femoral neck
g/cm2 0.87960.106 0.82260.124
Z score (SD) 20.4560.82 20.7560.99
aP , 0.002; bP , 0.006
Fig. 2. Bone mineral density (BMD) expressed as the Z score of lumbar
spine (L2-L4) and femoral neck in persistent young amenorrheic women
( ) and normal menstruating women in dialysis (h).
As shown in Figure 2, there was a significant correla-
tion between total serum estradiol and the Z score of
lumbar spine BMD in the amenorrheic women (r 5 0.45,
P , 0.01). A similar positive correlation was obtained
between total serum estradiol and absolute BMD values
expressed as g/cm2 (r 5 0.51, P , 0.01).
DISCUSSION
Our results demonstrate that young persistent amen-
orrheic women on dialysis have significantly lower tra-
Fig. 1. Correlation between serum concentrations of total estradiol becular BMD and increased bone resorption compared
and BMD expressed as the Z score of lumbar spine (L2-L4) in young
with regular menstruating women under similar condi-women in dialysis (r 5 0.45; P , 0.01).
tions of dialysis. The lower levels of estrogens in amenor-
rheic women and the correlation between estradiol and
lumbar spine BMD suggest that estrogen status may play
Serum creatinine, calcium, and phosphorus were similar an important role in bone mass conservation in uremic
in both groups. Serum alkaline phosphatase was higher women.
in the amenorrheic women (P , 0.01). The analysis of Most of the gynecological interest in women with
the hormone levels demonstrated lower total estradiol chronic renal failure on dialysis has been related to the
(P , 0.001) and higher FSH (P , 0.01) in the amenor- markedly reduced fertility observed in these patients.
rheic group when compared with the normal menstruat- Chronic renal failure in women is frequently accompa-
ing women, whereas LH was similar in both groups. nied by endocrine disturbances that could lead to men-
iPTH values were increased but were nonsignificantly strual, fertility, and other disorders. The postulated cause
different between groups. Serum levels of ICTP were for these alterations appears to be a defect in the hypo-
significantly elevated in the amenorrheic group when thalamic regulation of gonadotrophin secretion, result-
compared with the normal menstruating women. ing in lower estradiol peaks, lower FSH/LH ratios, and
Table 3 shows the absolute values of BMD in amenor- a higher prolactin concentration [14]. This could lead to
rheic and menstruating women. BMD at the lumbar anovulatory cycles and persistent amenorrhea. At the
spine was significantly lower in the amenorrheic group same time, hyperprolactinemia has been associated with
compared with menstruating women (0.997 6 0.16 vs. infertility and reduced sexual desire [15]. Dialysis treat-
1.163 6 0.07 g/cm2, P , 0.002). Likewise, as illustrated ment does not improve ovarian function, but after a
in Figure 1, the Z score that compares BMD in patients successful renal transplant, ovarian function and fertility
with age- and gender-matched controls was also lower are usually restored.
in the amenorrheic group (21.14 6 1.2 vs. 0.12 6 0.81, Women with chronic renal disease are frequently hy-
P , 0.006). In contrast, no differences in femoral neck poestrogenic as a result of the disease or its treatment.
BMD or Z score between both groups were observed In a recent study, Cochrane and Regan questioned 100
women with chronic renal failure (26 of them on chronic(Table 3).
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dialysis) about different gynecological aspects [16]. Men- effect of hyperparathyroidism [22–24]. The fact that
amenorrheic women had also lower BMD may suggeststrual disorders were present in 85% of the patients.
Menopause was found in one third of the patients, but that the lower estrogen levels may influence bone cell
activity. The adverse effects of hypoestrogenism on boneonly two of these women (6%) were offered hormonal
replacement therapy. This situation was not perceived have been widely recognized. The lack of estrogens is
associated with increased osteoclastic bone resorptionto be a problem by the treating nephrologists. Another
study evaluated 76 women on dialysis who were less probably by a direct effect, as well as by stimulating the
production of bone resorpting cytokines such as IL-1,than 55 years of age (68% on hemodialysis and 32% on
continuous ambulatory peritoneal dialysis). Of these, 44 IL-6, IL-11, and TNF-a [5–9]. In addition, estrogens may
affect PTH action by increasing PTH mRNA at the para-women (58%) were amenorrheic, and 21 (28%) were
postmenopausal. In the postmenopausal women group, thyroid gland [13] and modulating the PTH action on
bone. Indeed, studies in vitro have demonstrated thatonly one (4.8%) was receiving hormone replacement
therapy [17]. Thus, menopause in women on dialysis estrogen inhibits PTH-stimulated osteoclast formation
by directly affecting hemopoietic blast cell precursors byis not managed in the same way as in normal women,
and few postmenopausal women are being offered hor- a cAMP-mediated mechanism [25].
Clinical evidence in favor of a role of estrogen inmone replacement therapy. In our group of 53 postmeno-
pausal women, only 6 (11.3%) were on regular hormone uremic bone disease in women has been recently ad-
vanced by Matuszkiewicz-Rowin˜ska et al [26]. In theirreplacement therapy. Besides the lack of attention of
the treating physicians, women with end-stage renal fail- controlled study of a small group of postmenopausal
dialysis women, the treatment with transdermal estradiolure are usually stoical and rarely complain about gyneco-
logical problems that may seem trivial compared with and cyclic addition of norestisterone acetate significantly
increased lumbar spine BMD after one year.their renal disease.
Previous studies performed in nonuremic women with Another aspect in which estrogen deficiency could
play a role is the excessive cardiovascular morbidity andanovulatory cycles demonstrated lower bone mass than
regularly menstruating women [18, 19]. Our young amen- mortality observed in uremic patients. In a recent article,
Ginsburg et al demonstrated that hormone replacementorrheic dialysis patients demonstrated significant lower
BMD compared with similar patients with normal men- therapy in 11 postmenopausal women with end-stage
renal disease increased high-density lipoprotein choles-struation, suggesting that estrogen levels could be in part
responsible for the maintenance of the bone metabolism terol significantly to an extent that would be expected
to improve cardiovascular risk profile [27]. The role ofin these subjects. This could be one of the potential
explanations of why women on dialysis had proportion- estrogen replacement therapy in other comorbid condi-
tions observed in postmenopausal should be also ad-ately significantly lower BMD when compared with male
patients on dialysis [20]. dressed in women on dialysis.
Estrogen therapy in postmenopausal women couldAlthough the levels of estradiol in our young amenor-
rheic women were significantly lower than in normal have several beneficial effects as well as potentially seri-
ous risks. Currently, there are no long-term studies inmenstruating patients, they were within normal limits
for normal women. Previous studies have found that uremic women on hemodialysis or continuous ambula-
tory peritoneal dialysis that support the recommendationtotal and free estradiol levels are higher at baseline and
after estradiol administration in patients with end-stage of hormone replacement therapy to all postmenopausal
women. The decision to treat a postmenopausal womanrenal disease when compared with the control popula-
tion, suggesting that renal failure may decrease estradiol on dialysis with estrogens should be based on assessment
of the benefits and risks for that woman and their fullcatabolism and affect the pharmacokinetics of exogenous
estradiol [21]. The role of uremia in the peripheral action disclosure and discussion with her. Women taking long-
term unopposed estrogen therapy have an increased riskof this hormone has not been completely defined.
In our patients, serum iPTH was similarly elevated for endometrial carcinoma. As a result, nearly all women
who have not had a hysterectomy should be treated within both groups. Nevertheless, serum levels of alkaline
phosphatase and ICTP, markers of bone formation and estrogen and progestin.
Recent data suggest that as in the case of the femaleresorption, respectively, were significantly greater in the
amenorrheic women, suggesting a higher bone turnover skeleton, estrogens have more relevance than testoster-
one in the development or maintenance of the malein these patients. Although there has been demonstra-
tion of a good correlation between ICTP values and skeleton [28]. The role of estrogens in the bone alter-
ations of the male dialysis patients remains to be ex-histomorphometric parameters of bone resorption in dif-
ferent metabolic bone diseases, their values could have amined.
In summary, the role of persistent amenorrhea on thediurnal variations and in these patients could reflect cer-
tain serum accumulation with renal insufficiency or the bone alterations of young uremic patients should not be
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tors in undialyzed chronic renal failure, CAPD and hemodialysisoverlooked. Instead, female postmenopausal patients on
patients. Kidney Int 45:890–896, 1993
dialysis should be offered similar treatment opportuni- 12. Kitazawa R, Kimble RB, Vannice JL, Kung VL, Pacifici R:
Interleukin-1 receptor antagonist and tumor necrosis factor bind-ties than normal women. More prospective and con-
ing protein decrease osteoclast formation and bone resorption introlled studies are needed in this area. The potential ovariectomized mice. J Clin Invest 94:2397–2406, 1994
role of these alterations in the natural history of uremic 13. Naveh-Many T, Almogi G, Livni N, Silver J: Estrogen receptors,
and biologic response in rat parathyroid tissue and C-cells. J Clinosteodystrophy should be also clarified in the near future.
Invest 90:2434–2438, 1992
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